Race Oncology Ltd (ASX:RAC)'s Phillip Lynch provides a roadmap for the company's $29.7 million share purchase plan, designed to open the door on research opportunities for Race's Zantrene® anti-cancer agent. He says the company's drug candidate is able to both protect the heart from a new class of anti-cancer drug, known as carfilzomib, and improve its efficacy when it comes to killing cancer cells.
Race Oncology to explore anti-cancer agent's potential with $29.7 million SPP
